Vifor Fresenius Medical Care Renal Pharma and OPKO Health ink deal for Rayaldee

Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a joint venture between Vifor parent company Galenica and Fresenius Medical Care, and OPKO Health (NYSE: OPK), have entered into a collaboration and license agreement for the development and commercialization of Rayaldee (calcifediol)in Europe, Canada, Mexico, Australia, South Korea and certain other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency.

Under the terms of the agreement, the parties will also collaborate to develop and commercialize Rayaldee for the treatment of SHPT in dialysis patients, and OPKO has granted VFMCRP an option to acquire rights to the US market for treatment of dialysis patients.

OPKO to receive $52 million upfront plus milestones